A preclinical study demonstrated that combining Fc-enhanced or Fc-silent anti-TIGIT with anti-PD-1 in mice enhanced tumor control through distinct mechanisms: Fc-enhanced anti-TIGIT depleted intratumoral Treg, whereas Fc-silent anti-TIGIT enhances the activation of tumor-specific exhausted CD8 + T cells in a lymph node-dependent manner [41]. Here, PDCD1 is linked to neoplasm.